RIGEL PHARMACEUTICALS INC (RIGL)
Sector: Health Care
2026 Annual Meeting Analysis
RIGEL PHARMACEUTICALS INC · Meeting: May 14, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Dr. Hannah joined in May 2021 (within the 5-year window but more than 24 months ago), and Rigel's 3-year price return of +93.9% outperforms the XBI — SPDR S&P Biotech ETF's 3-year return of +68.2% by +25.7 percentage points, well below the 65-percentage-point threshold required to trigger an AGAINST vote under the strong-positive-TSR tier; she also has clear and relevant clinical development expertise.
Dr. Moos has served since 1997 and Rigel's 3-year price return of +93.9% outperforms the XBI — SPDR S&P Biotech ETF by +25.7 percentage points, far below the 65-percentage-point trigger threshold; no overboarding, attendance, or independence concerns are noted, and he has extensive relevant life sciences expertise.
Mr. Rodriguez serves as both CEO and a director; Rigel's 3-year price return of +93.9% outperforms the XBI — SPDR S&P Biotech ETF by +25.7 percentage points, which does not meet the 65-percentage-point threshold required to trigger an AGAINST vote; the TSR trigger does not fire, and no other director-level policy concerns apply.
All three nominees pass the TSR screen — Rigel's 3-year price return of +93.9% beats the XBI — SPDR S&P Biotech ETF benchmark by +25.7 percentage points, well short of the 65-percentage-point threshold needed to trigger concern under the strong-positive-TSR tier. No overboarding, attendance, independence, or qualification issues were identified for any nominee.
Say on Pay
✓ FORCEO
Raul R. Rodriguez
Total Comp
$4,658,805
Prior Support
N/A
CEO Raul R. Rodriguez received total compensation of $4,658,805 in fiscal year 2025, which is reasonable for a CEO of a ~$509 million market-cap commercial-stage biotechnology company. The company's pay structure includes a meaningful equity component in the form of stock options and RSUs, and the proxy discloses a formal clawback policy adopted in August 2023 that allows recoupment of incentive pay in the event of a financial restatement. Rigel's stock has returned +93.9% over three years versus +68.2% for the XBI — SPDR S&P Biotech ETF, indicating that incentive pay has been earned in the context of genuine shareholder value creation.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
$1,820,000
Non-Audit Fees
$0
Ernst & Young LLP received $1,820,000 in audit fees for fiscal year 2025 and zero in non-audit fees (audit-related, tax, and all other fees were each $0), meaning the non-audit fee ratio is 0% — well below the 50% threshold that would raise independence concerns. Auditor tenure is not disclosed in the filing, so the tenure trigger cannot fire per policy. EY is a Big 4 firm appropriate for a company of Rigel's size, and no material restatements were disclosed.
Overall Assessment
Rigel's 2026 annual meeting ballot is straightforward — all three director nominees pass the TSR screen given strong outperformance versus the XBI — SPDR S&P Biotech ETF over three years, CEO pay is reasonable and backed by a formal clawback policy, and Ernst & Young LLP has a clean fee profile with zero non-audit fees. The two equity plan proposals (2018 Plan share increase and ESPP share increase) fall outside the current voting policy scope and are noted separately for shareholder consideration.